COGT

Cogent Biosciences, Inc.

Healthcare
Biotechnology
$5.71B market cap

Forecast run · Sep 14, 2026Upside rank 666 of 3,136

Model Signal

ForecastQ Daily Probabilities

51.8%

17.2%

18.8%

Analyst Consensus

Recommendation2.17/5 Buy

Last price$33.41

Price target$51.75

Implied move+54.9%

Analysts12

ForecastQ Portfolios

COGT is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.